COMMUNIQUÉS West-GlobeNewswire

TCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuC™-T Cells
07/05/2019
Preclinical study results published in Nature Communications show superior anti-tumor activity of T cell receptor fusion construct T cells (TRuC™)-T cells compared to chimeric antigen receptor (CAR)-T cells in several [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2019
07/05/2019
I n f ormation relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2019 Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : Euronext [...]
CORRECTION: ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019
07/05/2019
Orion Corporation NOTIFICATION 07.05.2019 at 09:45 CORRECTION: Total Price was incorrect in previous notification. Below is the correct release. ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019 Date 06.05.2019 [...]
CellaVision AB: Interim report January-March 2019
07/05/2019
Good performance in all regions generated strong organic growth January 1-March 31, 2019 Net sales increased by 34% to SEK 103.9 million (77.6). Organic growth was 31% (-20). Operating profit increased to SEK 34.9 [...]
Nexstim Plc: Offer shares have been registered
07/05/2019
Company announcement, Helsinki, 7 May 2019 at 9.00 AM Nexstim Plc: Offer shares have been registered Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( " Nexstim " or " Company " ), the targeted neuromodulation company developing and [...]
MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America
07/05/2019
$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones Leverages Vericel’s Commercial Capabilities and Presence in U.S. Burn Care Market Biologics License Application (BLA) Filing [...]
SPINEWAY : Réduction du capital social
07/05/2019
Réduction du capital social de Spineway Conformément à la deuxième et troisième résolutions de l’Assemblée Générale Mixte du 4 avril 2019, la Société Spineway a procédé à la réduction de capital social d’un montant de 2 [...]
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
07/05/2019
Nebulized ensifentrine as add-on to dual bronchodilator therapy for COPD demonstrated additional increase in lung function on top of maximum current therapy in three-day Phase 2 clinical trial Single dose of [...]
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
07/05/2019
LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2b [...]
Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
07/05/2019
Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints Highly Synergistic with Existing Commercial Franchise and Significantly Expands Vericel’s Presence in the Severe Burn Care Market CAMBRIDGE, [...]
Immunicum AB (publ) Announces Upcoming Conferences in May and June
07/05/2019
Press Release 7 May 2019 Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in May and June. 30 th Annual Cancer Progress Conference Date: [...]
Demant A/S: Interim Management Statement covering the period year-to-date
07/05/2019
Company announcement no 2019-06 7 May 2019 Interim Management Statement covering the period year-to-date Successful launch of Oticon Opn S drives growth acceleration after slow start to the year Product launches [...]
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
07/05/2019
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS)[1], a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only [...]
Bone Therapeutics Provides First Quarter 2019 Business Update
07/05/2019
Regulated information Phase II ALLOB Spinal Fusion results expected mid-June Well-positioned to advance product pipeline into late-stage clinical development Strengthened the executive management team with key positions [...]
Bone Therapeutics publie son rapport d’activité du premier trimestre 2019
07/05/2019
Information réglementée Présentation des résultats phase II ALLOB Fusion Vertébrale mi-juin Préparation de 2 études cliniques de phase III Renforcement de l’équipe de direction à des postes clés Gosselies (Belgique), le [...]
EssilorLuxottica : Solid revenue growth in the first quarter, Full-year objectives confirmed
07/05/2019
Solid revenue growth in the first quarter Full-year objectives confirmed Revenue growth of 7.5% (+3.7% at constant exchange rates 3 ) Sustained momentum in Essilor’s Lenses & Optical Instruments and in Luxottica’s [...]
EssilorLuxottica: Croissance solide du chiffre d’affaires au premier trimestre, Objectifs annuels confirmés
07/05/2019
Croissance solide du chiffre d’affaires au premier trimestre Objectifs annuels confirmés Chiffre d’affaires en hausse de 7,5 %, dont 3,7 % à taux de change constants 3 Dynamique soutenue dans les divisions Verres et [...]
Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting
07/05/2019
EMERYVILLE, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders [...]
Dr. James Chappuis Atlanta´s Most-Coveted Spinal Specialist
07/05/2019
James L. Chappuis MD FACS Atlanta, Georgia, May 06, 2019 (GLOBE NEWSWIRE) -- For the last 28 years, Dr. James Chappuis an Atlanta based Spinal specialist has been a visionary in his field, Dr. James L. Chappuis FACS [...]

Pages